MOLECULAR BASIS FOR PLATELET FUNCTION IN HEMOSTASIS
血小板止血功能的分子基础
基本信息
- 批准号:6638661
- 负责人:
- 金额:$ 132.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-05-01 至 2005-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This Program Project, under the direction of Robert W. Coleman, Molecular Basis for Platelet Function in Hemostasis, will exist within the Sol Sherry Thrombosis Research Center of Temple University School of Medicine. The Center is a formally established research institute within the School of Medicine dedicated to advancing our understanding of the etiology/pathogenesis, diagnosis and treatment of arterial and venous thrombosis and hemorrhagic diseases. To fulfill this goal, investigators in this project will examine the mechanisms of activation of platelets in hemostasis and thrombogenesis. Each project in the present proposal has the potential to indicate or provide the foundation for development of an appropriate inhibitory drug or therapeutic approach to prevent platelet activation, aggregation, and coagulant activity. and second messengers in particular, cyclic nucleotides and platelet coagulant activities. Project 1, Active Site Amino Acids of cAMP Phosphodiesterase 3A (R.W. Colman), concentrates on the delineation on the critical amino acids in active sites of the major cAMP phosphodiesterase in platelet. The amino acids critical for catalysis and metal binding of type 3A PDE will be identified by affinity labeling and site-directed mutagenesis. Project 2, Platelet Factor XI (P.N. Walsh), will structurally characterize platelet factor XI and study the mechanism of agonist exposure of actor XI in platelets. The mode of activation, cellular localization, and functional characteristics of platelet factor XI will be investigated. Project 3, Signal Transduction Defects in Human Platelets (A.K. Rao), will seek new insights into platelet signal transduction mechanisms by the biochemical and molecular biological dissection of the defects of a selected group of patients with qualitative defects focusing on abnormalities in PLC-b1a and Gaq. Project 4, Platelet ADP Receptors (S.P. Kunapuli), will elucidate the role of 3 ADP receptor subtypes in platelet fibrinogen receptor activation. Core A, Administration (R.W. Colman), will provide fiscal oversight and clerical support for all projects. Core B, Cell Culture (S.P. Kunapuli), will facilitate and support all of the projects and thus efficiently expedite the research. Core C, Flow Cytometry (J.K. deRiel), will provide fluorescent-activated cell analysis and confocal services to all projects. All of these investigators have a history of collaborative research with more than one of the other project leaders and will consult and share intellectual and physical resources with the other project leaders. The knowledge gained from these studies will provide therapeutic approaches to enhancing hemostasis and preventing thrombosis.
该项目由Robert W. Coleman教授指导,“血小板功能在止血中的分子基础”,将在天普大学医学院的Sol Sherry血栓研究中心进行。该中心是医学院内正式成立的研究机构,致力于推进我们对动脉和静脉血栓形成和出血性疾病的病因/发病机制,诊断和治疗的理解。为了实现这一目标,本项目的研究人员将研究血小板在止血和血栓形成中的激活机制。本提案中的每个项目都有可能为开发适当的抑制性药物或治疗方法提供基础,以防止血小板活化、聚集和凝血活性。尤其是第二信使,环核苷酸和血小板凝血活性。项目1,cAMP磷酸二酯酶3A活性位点氨基酸(R.W. Colman),集中描述血小板中主要cAMP磷酸二酯酶活性位点的关键氨基酸。对3A型PDE的催化和金属结合至关重要的氨基酸将通过亲和标记和定点诱变来鉴定。项目2,血小板因子XI (P.N. Walsh),将对血小板因子XI进行结构表征,并研究因子XI在血小板中的激动剂暴露机制。我们将研究血小板因子XI的激活方式、细胞定位和功能特征。项目3,人类血小板信号转导缺陷(A.K. Rao),将通过对一组定性缺陷患者的缺陷进行生化和分子生物学解剖,重点研究PLC-b1a和Gaq的异常,寻求血小板信号转导机制的新见解。项目4,血小板ADP受体(S.P. Kunapuli),将阐明3种ADP受体亚型在血小板纤维蛋白原受体激活中的作用。核心A,行政(R.W.科尔曼),将为所有项目提供财政监督和文书支持。核心B,细胞培养(S.P. Kunapuli),将促进和支持所有的项目,从而有效地加快研究。核心C,流式细胞术(jk deRiel),将为所有项目提供荧光激活细胞分析和共聚焦服务。所有这些研究人员都有与一个以上的其他项目负责人合作研究的历史,并将与其他项目负责人咨询和共享智力和物质资源。从这些研究中获得的知识将为加强止血和预防血栓形成提供治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert W Colman其他文献
Effect of Anti-P1<sup>A1</sup> Antibody on Human Platelets. II. Mechanism of the Complement-Dependent Release Reaction
- DOI:
10.1182/blood.v53.4.578.578 - 发表时间:
1979-04-01 - 期刊:
- 影响因子:
- 作者:
Alan D Schreiber;Douglas B Cines;Chester Zmijewski;Robert W Colman - 通讯作者:
Robert W Colman
Robert W Colman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert W Colman', 18)}}的其他基金
Innate Immunity in Experimental Arthritis of Kininogen
激肽原实验性关节炎的先天免疫
- 批准号:
6948560 - 财政年份:2004
- 资助金额:
$ 132.37万 - 项目类别:
Innate Immunity in Experimental Arthritis of Kininogen
激肽原实验性关节炎的先天免疫
- 批准号:
7121265 - 财政年份:2004
- 资助金额:
$ 132.37万 - 项目类别:
Innate Immunity in Experimental Arthritis of Kininogen
激肽原实验性关节炎的先天免疫
- 批准号:
7020439 - 财政年份:2004
- 资助金额:
$ 132.37万 - 项目类别:
Innate Immunity in Experimental Arthritis of Kininogen
激肽原实验性关节炎的先天免疫
- 批准号:
6838311 - 财政年份:2004
- 资助金额:
$ 132.37万 - 项目类别:
Innate Immunity in Experimental Arthritis of Kininogen
激肽原实验性关节炎的先天免疫
- 批准号:
7280950 - 财政年份:2004
- 资助金额:
$ 132.37万 - 项目类别:
Active site amino acids of cAMP phosphodiesterase 3A
cAMP磷酸二酯酶3A的活性位点氨基酸
- 批准号:
6570526 - 财政年份:2002
- 资助金额:
$ 132.37万 - 项目类别:
Active site amino acids of cAMP phosphodiesterase 3A
cAMP磷酸二酯酶3A的活性位点氨基酸
- 批准号:
6587891 - 财政年份:2002
- 资助金额:
$ 132.37万 - 项目类别:
ANTIADHESIVE AND ANTICOAGULANT ACTIVITY OF KININOGENS
激肽原的抗粘连和抗凝血活性
- 批准号:
6485294 - 财政年份:2001
- 资助金额:
$ 132.37万 - 项目类别:
Active site amino acids of cAMP phosphodiesterase 3A
cAMP磷酸二酯酶3A的活性位点氨基酸
- 批准号:
6448223 - 财政年份:2001
- 资助金额:
$ 132.37万 - 项目类别:
MOLECULAR BASIS FOR PLATELET FUNCTION IN HEMOSTASIS
血小板止血功能的分子基础
- 批准号:
6748112 - 财政年份:2000
- 资助金额:
$ 132.37万 - 项目类别:
相似海外基金
Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology
利用临床和分子病理学的相似性,加速罕见神经系统、神经代谢和神经肌肉疾病的药物再利用
- 批准号:
10077172 - 财政年份:2023
- 资助金额:
$ 132.37万 - 项目类别:
EU-Funded
Molecular pathology investigation for targeted therapy of intractable pediatric epilepsy via mTOR pathway hyperactivation
mTOR通路过度激活靶向治疗顽固性小儿癫痫的分子病理学研究
- 批准号:
23K07339 - 财政年份:2023
- 资助金额:
$ 132.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular pathology in special type of colonic adenocarcinoma
特殊类型结肠腺癌的分子病理学
- 批准号:
22K15430 - 财政年份:2022
- 资助金额:
$ 132.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigating the molecular pathology of WDR26 deficiency
研究 WDR26 缺陷的分子病理学
- 批准号:
472604 - 财政年份:2022
- 资助金额:
$ 132.37万 - 项目类别:
Operating Grants
Cell-type-specific molecular pathology of ALS in U.S. military Veterans
美国退伍军人 ALS 的细胞类型特异性分子病理学
- 批准号:
10254543 - 财政年份:2021
- 资助金额:
$ 132.37万 - 项目类别:
Unraveling the molecular pathology of retinal degeneration through single cell genomics
通过单细胞基因组学揭示视网膜变性的分子病理学
- 批准号:
10211475 - 财政年份:2021
- 资助金额:
$ 132.37万 - 项目类别:
Cell-type-specific molecular pathology of ALS in U.S. military Veterans
美国退伍军人 ALS 的细胞类型特异性分子病理学
- 批准号:
10513300 - 财政年份:2021
- 资助金额:
$ 132.37万 - 项目类别:
Translating molecular pathology into cancer diagnostics
将分子病理学转化为癌症诊断
- 批准号:
nhmrc : 1193630 - 财政年份:2021
- 资助金额:
$ 132.37万 - 项目类别:
Investigator Grants